Received Jan 14, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | FX753 | — |
Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 56-year-old male patient who received Herpes zoster (Shingrix) (batch number FX753, expiry date 07-JUL-2027) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 14-MAY-2024). On 13-JAN-2026, the patient received the 1st dose of Shingrix. On 13-JAN-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 13-JAN-2026 The general response center transfers a registered pharmacist (general response center did not raise an adverse event and did not identify the adverse event in this request). The registered pharmacist asks if the patient could receive a third dose of Shingrix vaccine, the pharmacist states that the patient was not sure if the vaccine was administered (the patient did not remember receiving that shot). The vaccine administration facility was the same as primary reporter.